What happened
Sam-A Pharm reported consolidated results for FY2025: revenue of US$54.5M (−18.6% year on year), operating profit of US$7.69M (−55.1% year on year) and net income of US$9.07M (−41.4% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$54.5M |
|---|---|
| Revenue vs a year earlier | −18.6% |
| Operating profit | US$7.69M |
| Net income | US$9.07M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-26, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260226901795 → open original filing |
Source: DART. Information only, not investment advice.